DK

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences

Retrieved on: 
Friday, March 1, 2024
EVP, Exercise, Hubli railway division, Conference, Phase II, SMA, Safety, Muscular Dystrophy Association, Science, Fatigue, Muscle weakness, Patient, NMD, Poster, Myasthenia gravis, Phase, MDA, Trial of the century, Congress, Pharmaceutical industry

ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.

Key Points: 
  • ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.
  • ClC-1 inhibition could be a possible mechanism to improve muscle fiber activation to address muscle weakness and fatigue in neuromuscular diseases.
  • Details of NMD Pharma’s poster presentations are below:
    The 4th Scientific International Congress on SMA is taking place in Ghent, Belgium, from 14-16 March.
  • : NMD Pharma be presenting one poster and one oral presentation at the congress.

Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference

Retrieved on: 
Friday, March 1, 2024
Nasdaq Copenhagen, Conference

Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, Chief Executive Officer, will present at TD Cowen’s 44th Annual Health Care Conference in Boston on Monday, March 4 at 1:30 – 2:00 p.m.
  • ET (7:30 – 8:00 p.m. CET).
  • A webcast of the presentation will be available at https://wsw.com/webcast/cowen154/zeal.co/2411784 and accessible through the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/ where a replay will also be archived following the presentation.

POTENTIAL NEW BOND ISSUE

Retrieved on: 
Friday, March 1, 2024
NOK, Danske Bank

DFDS, rated BBB-/Stable by Scope Ratings, intends to issue NOK denominated senior unsecured bonds with expected tenors of 3-5 years in the near future.

Key Points: 
  • DFDS, rated BBB-/Stable by Scope Ratings, intends to issue NOK denominated senior unsecured bonds with expected tenors of 3-5 years in the near future.
  • Danske Bank, Nykredit, and SEB have been mandated to arrange a General Investor Call on Monday 4 March 2024.
  • There is no certainty that the issue of the bonds will be initiated or consummated.
  • The proceeds from the potential bond issue are to be used for general corporate purposes.

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Retrieved on: 
Thursday, February 29, 2024
EST, Infection, Patient, Research and development, Cancer

The R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development.

Key Points: 
  • The R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development.
  • The event will highlight the unique predictive capabilities that differentiate the platform and how these can help address severe unmet medical needs for patients with cancer and infectious diseases.
  • The event will take place at Evaxion’s facilities in Hørsholm, Denmark, and will also be accessible via live webcast.
  • A replay of the presentations will be available on our website following the event.

Allarity Therapeutics to Present at Biomarkers 2024

Retrieved on: 
Wednesday, February 28, 2024
CDX, Therapy, Biomarker, Ovarian cancer, Research, Patient, Pharmaceutical industry

Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.

Key Points: 
  • Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.
  • Thomas Jensen, CEO and co-founder of Allarity, will present the company's novel work in developing the drug-specific Drug Response Predictor (DRP®) companion diagnostics (CDx) platform.
  • The study is being conducted at multiple sites across the US and Europe.
  • Mr. Jensen will be available for individual meetings to explore business development prospects.

Zealand Pharma Announces Financial Results for the Full Year 2023

Retrieved on: 
Tuesday, February 27, 2024
DREAM, F2, F1, Overweight, Obesity, Weight loss, Part, F3, Human, Boehringer Ingelheim, BMI, NASH, Fatty liver disease, Zealand Pharma

In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.

Key Points: 
  • In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.
  • In February 2024, Boehringer Ingelheim and Zealand Pharma announced positive results from the Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).
  • In December 2023, Zealand submitted an NDA to the U.S. FDA for the treatment of adult patients with SBS dependent on parenteral support.
  • A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/ .

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Retrieved on: 
Monday, February 26, 2024
Fibrosis, Obesity, MASH, Boehringer Ingelheim, Zealand Pharma, Pharma, Liver disease, Fine chemical

The trial met its primary endpoint with survodutide reaching a biopsy-proven improvement in MASH after 48 weeks, without worsening of fibrosis stages F1, F2 and F3 (mild to moderate or advanced scarring).

Key Points: 
  • The trial met its primary endpoint with survodutide reaching a biopsy-proven improvement in MASH after 48 weeks, without worsening of fibrosis stages F1, F2 and F3 (mild to moderate or advanced scarring).
  • Survodutide also met all secondary endpoints, including a statistically significant improvement in liver fibrosis.
  • The double-blind, placebo-controlled Phase 2 trial studied three doses of survodutide at 2.4 mg, 4.8 mg, and 6.0 mg. Top-line results demonstrated an improvement in MASH, at all doses explored in the trial.
  • Treatment with survodutide did not show unexpected safety or tolerability issues, including at the higher dose of 6.0 mg.

MC2 Therapeutics to Present at Upcoming Conferences

Retrieved on: 
Monday, February 26, 2024
Inflammation, Therapy, Conference, Dermatology, American Academy

Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today that its leadership will attend and present at the following industry conferences:

Key Points: 
  • Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today that its leadership will attend and present at the following industry conferences:
    17th Annual European Life Sciences CEO Forum, Zürich February 28th-29th (presentation at 3:20pm CET, February 28th - Track C - Room Panorama C)
    TD Cowen Annual Health Care Conference, Boston March 4th-6th (hosting 1:1 meetings with investors on March 4th at the event)
    American Academy of Dermatology Annual Meeting, San Diego March 8th-12th
    Any webcasts will be available on MC2’s website following the presentations.
  • Please contact us if you would like to arrange a meeting.

Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency

Retrieved on: 
Friday, February 23, 2024
Marketing, EMA, Marketing Authorisation Application, Committee, MAA, Food, BLA, Nature, Vaccination, CHMP, European Medicines Agency, Public, Chikungunya, OMX, Ageing, CHIKV, Vaccine

Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.

Key Points: 
  • Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.
  • COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for CHIKV VLP, the Company’s investigational chikungunya vaccine.
  • Bavarian Nordic is on track and plans to submit its MAA for CHIKV VLP to the EMA during H1 2024.
  • “We are pleased to receive the accelerated assessment in recognition of our chikungunya vaccine candidate and our efforts to bring this novel product to the market.

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Retrieved on: 
Tuesday, February 20, 2024
MSD, Infection, Organization, Merck, Merck & Co., AI, Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points: 
  • COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).
  • Further, we are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase.
  • Using Evaxion's proprietary platform, AI-Immunology™, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.
  • The conclusion of the antigen discovery and design phases marks a significant milestone for the development of the vaccine candidate, EVX-B3.